Heat Biologics
Scorpius Holdings Inc., via Scorpius BioManufacturing, is a CDMO accelerating biologic programs from development to clinic and beyond.
Launch date
Employees
Market cap
CAD8.3m
Enterprise valuation
CAD8m (Public information from Apr 2024)
Share price
€10 HTBX
Chapel Hill North Carolina (HQ)
Financials
Estimates*
USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Revenues | 3.0m | 3.0m | 2.0m | 6.0m | 7.0m | 20.6m | 35.1m |
% growth | (50 %) | - | (33 %) | 200 % | 17 % | 194 % | 70 % |
EBITDA | (19.2m) | (24.6m) | (32.9m) | (42.5m) | (34.5m) | - | - |
% EBITDA margin | (639 %) | (820 %) | (1647 %) | (708 %) | (493 %) | - | - |
Profit | (20.0m) | (26.0m) | (35.0m) | (43.0m) | (45.2m) | (22.2m) | (16.6m) |
% profit margin | (667 %) | (867 %) | (1750 %) | (717 %) | (646 %) | (108 %) | (47 %) |
EV / revenue | 1.1x | 4.2x | -8.6x | -2.4x | 3.3x | 0.3x | 0.2x |
EV / EBITDA | -0.2x | -0.5x | 0.5x | 0.3x | -0.7x | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $250k | Seed | |
N/A | $2.8m | Series A | |
N/A | $5.1m | Growth Equity VC | |
N/A | N/A | IPO | |
$7.5m | Post IPO Debt | ||
N/A | $20.7m | Post IPO Equity | |
N/A | $13.8m | Post IPO Equity | |
* | N/A | $7.0m | Post IPO Equity |
* | N/A | $2.3m | Post IPO Debt |
Total Funding | CAD11.1m |
Related Content
Recent News about Heat Biologics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Heat Biologics
EditACQUISITION by Heat Biologics Apr 2022